Lung cancer study tests adding precise radiation after targeted therapy
NCT ID NCT06613633
First seen Apr 30, 2026 · Last updated Apr 30, 2026
Summary
This study looked at 4000 people with advanced EGFR-mutant non-small cell lung cancer who had already received a third-generation targeted therapy (EGFR-TKI). The goal was to see if adding a precise type of radiation (stereotactic radiotherapy) to remaining tumors could be a safe and effective next step. Researchers tracked when tumors shrank the most, where leftover tumors were located, and how the disease progressed after resistance to the drug.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Shanghai Cancer Center
Shanghai, Shanghai Municipality, 200050, China
-
Shanghai Chest Hospital
Shanghai, Shanghai Municipality, China
-
Wuhan Tongji Hospital
Wuhan, Hubei, 430030, China
Conditions
Explore the condition pages connected to this study.